Home › Compound Library › Selank

Selank

Peptideinsufflated · inferred

Synthetic heptapeptide analog of tuftsin with anxiolytic and nootropic properties, developed at the Institute of Molecular Genetics (Russia). Plasma half-life ~15-20 min but pharmacodynamic effects last hours. Modulates GABAergic neurotransmission and IL-6 expression. Administered intranasally.

Projected serum levels — 250 mcg (≈ 0.25 mg), once daily

Selank
Selank modeled serum levels, 250 mcg (≈ 0.25 mg) once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 250 mcg (≈ 0.25 mg) once daily (insufflated).

Modeled steady state after ~1 days: peak ≈ 0.037 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Peptide
Route modeled
Insufflated
Model confidence
inferred
Half-life
14 min
Common dose
250 mcg (≈ 0.25 mg)
Suggested maximum
750 mcg/day
Reference dose range
125–750 mcg (single dose)
Suggested cadence
once daily

Documented interactions

  • danger
    25I-NBOMe + Selank Serotonin risk

    25I-NBOMe and Selank both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Selank Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Selank both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Selank Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Selank both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-AcO-DMT (Psilacetin) + Selank Serotonin risk

    4-AcO-DMT (Psilacetin) and Selank both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) + Selank Serotonin risk

    5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) and Selank both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) + Selank Serotonin risk

    6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) and Selank both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 105 modeled interaction pairings for selank across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission Volkova A et al. · Frontiers in Pharmacology, 2016 DOI

    Demonstrated Selank modulates expression of 45 genes involved in GABAergic neurotransmission in the frontal cortex and hippocampus, providing a molecular basis for its anxiolytic effects.

  2. Anxiolytic-like effect of the neuropeptide selank on a conflict model in outbred ICR mice Sarkisova KY et al. · Bulletin of Experimental Biology and Medicine, 2008 DOI

    Confirmed anxiolytic effects of Selank in a punished drinking conflict paradigm comparable to benzodiazepines but without sedation or motor impairment.

  3. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in generalized anxiety disorders and neurasthenia Zozulya AA et al. · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008 DOI

    Clinical study showing Selank demonstrated significant anxiolytic efficacy comparable to medazepam in patients with generalized anxiety disorder and neurasthenia.

3 published studies referenced in the app, each with a plain-language summary.